Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.7, Iss.8, 2006-06, pp. : 1055-1064

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Exenatide enhances standard therapy in type 2 diabetes mellitus

Inpharma, Vol. 1, Iss. 1445, 2004-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus

By Gallwitz Baptist

Drug Safety, Vol. 33, Iss. 2, 2010-02 ,pp. : 87-100

Adis International

Access to resources Recommend Favorite

Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

By Holst Jens Juul

Expert Opinion on Emerging Drugs, Vol. 9, Iss. 1, 2004-05 ,pp. : 155-166

Informa Healthcare

Access to resources Recommend Favorite

Exenatide once weekly in type 2 diabetes mellitus

By Bischoff Lindsay A Jabbour Serge A Miller Jeffrey L

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 8, 2011-06 ,pp. : 1297-1303

Informa Healthcare

Access to resources Recommend Favorite

Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

By Ahrén Bo

European Diabetes Nursing, Vol. 10, Iss. 1, 2013-03 ,pp. : 31-36

Blackwell Publishing

Access to resources Recommend Favorite